NYSE:DGX
QUEST DIAGNOSTICS INC
A national laboratory services leader providing comprehensive clinical testing and diagnostics to US healthcare systems and patients.
Key Metrics
Investment Thesis
Bull Case
Investors may favor Quest Diagnostics for its dominant market position in US laboratory services and its critical role in the clinical trial ecosystem, which offers stable, recurring revenue streams. The company's scale allows it to invest heavily in automation and new test development, potentially capturing share from smaller competitors as the industry consolidates. With a strong operating cash flow profile and a history of returning capital through dividends and share repurchases, the stock offers a defensive growth characteristic typical of established healthcare infrastructure plays.
Bear Case
Concerns regarding the company's high debt load, with total liabilities exceeding $9B against shareholders' equity of only $7.21B, could limit financial flexibility during interest rate hikes or credit tightening. The historical revenue stagnation between 2022 and 2023 suggests potential saturation in the routine testing market or persistent payer pushback on pricing, which may dampen future growth prospects. Significant accumulated retained earnings deficits indicate past periods of capital depletion that investors should monitor to ensure sustainable profitability without aggressive cost-cutting.
About QUEST DIAGNOSTICS INC
Quest Diagnostics Inc. is a leading US-based laboratory services provider operating a nationwide network of laboratories that perform clinical testing and diagnostics. The company serves healthcare systems, physicians, and patients across the United States with a focus on pathology, microbiology, immunohistochemistry, and anatomic pathology. Its integrated platform combines high-throughput testing capabilities with digital health solutions to deliver rapid and accurate diagnostic results.
Analysis
Management Discussion
Quest Diagnostics reported revenue of $11.04B and net income of $1.05B in the latest year, marking a recovery from the prior two years where revenue hovered around $9.25B-$9.87B and net income dipped below $1B. Strong operating cash flow of $1.89B and a CFO-to-net-income ratio of 1.79 indicate robust operational efficiency despite significant capital expenditures of $527M. The company successfully navigated recent headwinds to return to growth, though the substantial long-term debt of $5.17B remains a key balance sheet consideration.
Industry Overview
The US laboratory services industry is characterized by high consolidation trends as payers and providers seek efficiency through centralized testing networks. Advancements in molecular diagnostics, liquid biopsy, and genetic testing are driving the shift from routine chemistry panels to higher-margin specialized tests. Regulatory oversight by CMS and CLIA ensures strict quality standards but creates a complex compliance environment that favors large players with dedicated regulatory teams.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $9.88B | $9.25B | $9.87B | $11.04B |
| Cost of Revenue | $6.45B | $6.20B | $6.63B | $7.37B |
| Gross Profit | $3.43B | $3.05B | $3.24B | $3.67B |
| Operating Expenses | $2.00B | $1.79B | $1.90B | $2.11B |
| Operating Income | $1.43B | $1.26B | $1.35B | $1.56B |
| G&A | $1.87B | $1.64B | $1.77B | $1.97B |
| Stock-Based Comp | $77.0M | $77.0M | $88.0M | $88.0M |
| D&A | $437.0M | $439.0M | $493.0M | $570.0M |
| Depreciation | $317.0M | $331.0M | $366.0M | $416.0M |
| Amortization | $120.0M | $108.0M | $127.0M | $154.0M |
| Other OpEx | $131.0M | $149.0M | $128.0M | $142.0M |
| Non-Operating Income | $-193.0M | $-132.0M | $-171.0M | $-238.0M |
| Interest Expense | $148.0M | $163.0M | — | — |
| Pre-Tax Income | $1.24B | $1.13B | $1.18B | $1.32B |
| Income Tax | $264.0M | $248.0M | $273.0M | $314.0M |
| Continuing Ops | $971.0M | $882.0M | $902.0M | $1.00B |
| Discontinued Ops | $44.0M | $26.0M | $19.0M | $42.0M |
| Net Income | $1.01B | $908.0M | $921.0M | $1.05B |
| Minority Interest | $69.0M | $54.0M | $50.0M | $54.0M |
| Net to Common | $946.0M | $854.0M | $871.0M | $992.0M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $1.90B | $2.37B | $2.39B | $2.38B |
| Cash & Equivalents | $315.0M | $686.0M | $549.0M | $420.0M |
| Accounts Receivable | $1.20B | $1.21B | $1.30B | $1.41B |
| Inventory | $192.0M | $190.0M | $188.0M | $189.0M |
| Prepaid Expenses | $196.0M | $286.0M | $351.0M | $361.0M |
| Other Current Assets | $0 | $0 | $0 | $0 |
| Long-Term Assets | $10.94B | $11.65B | $13.76B | $13.85B |
| PP&E (Net) | $1.77B | $1.82B | $2.11B | $2.20B |
| Intangibles | $1.09B | $1.17B | $1.76B | $1.64B |
| Goodwill | $7.22B | $7.73B | $8.86B | $8.95B |
| Operating Leases | $585.0M | $602.0M | $651.0M | $657.0M |
| Other LT Assets | $144.0M | $198.0M | $255.0M | $270.0M |
| Total Assets | $12.84B | $14.02B | $16.15B | $16.23B |
| Current Liabilities | $1.55B | $1.81B | $2.17B | $2.28B |
| Current Debt | $2.0M | $303.0M | $602.0M | $504.0M |
| Current Leases | $153.0M | $153.0M | $173.0M | $174.0M |
| Taxes Payable | $2.0M | $0 | — | $18.0M |
| Other Current Liab | $928.0M | $993.0M | $1.00B | $1.16B |
| Long-Term Liabilities | $5.36B | $5.87B | $7.17B | $6.74B |
| Long-Term Debt | $3.98B | $4.41B | $5.62B | $5.17B |
| LT Operating Leases | $489.0M | $503.0M | $535.0M | $537.0M |
| Other LT Liab | $889.0M | $952.0M | $1.02B | $1.04B |
| Total Liabilities | $6.91B | $7.68B | $9.34B | $9.02B |
| Shareholders' Equity | $5.93B | $6.34B | $6.81B | $7.21B |
| Retained Earnings | $8.29B | $8.82B | $9.36B | $9.99B |
| AOCI | $-21.0M | $-14.0M | $-88.0M | $-27.0M |
| Treasury Stock | $4.67B | $4.83B | $4.86B | $5.18B |
| Total L&E | $12.84B | $14.02B | $16.15B | $16.23B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $1.01B | $908.0M | $921.0M | $1.05B |
| Non-Cash Adjustments | $1.18B | $333.0M | $314.0M | $584.0M |
| Working Capital Changes | $-479.0M | $31.0M | $99.0M | $256.0M |
| Cash from Operations | $1.72B | $1.27B | $1.33B | $1.89B |
| Capital Expenditures | $404.0M | $408.0M | $425.0M | $527.0M |
| Cash from Investing | $-543.0M | $-1.06B | $-2.55B | $-631.0M |
| Share Buybacks | $1.41B | $275.0M | $151.0M | $450.0M |
| Dividends Paid | $305.0M | $314.0M | $331.0M | $353.0M |
| Cash from Financing | $-1.73B | $160.0M | $1.08B | $-1.39B |
| FX Effect | $0 | $0 | $-7.0M | $4.0M |
| Net Change in Cash | $-557.0M | $371.0M | $-137.0M | $-129.0M |
| Beginning Cash | $872.0M | $315.0M | $686.0M | $549.0M |
| Ending Cash | $315.0M | $686.0M | $549.0M | $420.0M |
Frequently Asked Questions
How does QUEST DIAGNOSTICS INC make money?
The company's revenue is primarily driven by its Laboratory Services segment, which includes routine testing, molecular diagnostics, and specialized pathology. Additional revenue streams come from its Clinical Trials business supporting pharmaceutical research, as well as sales of reagents, consumables, and diagnostic equipment. The company also offers digital health solutions including electronic medical record integration and telepathology services.
What are the main risks for DGX?
Regulatory changes or reimbursement rate reductions from payers could materially impact the company's large volume of routine testing revenue. The high fixed-cost structure of operating numerous laboratory facilities creates vulnerability to sustained declines in patient volume or adverse economic conditions affecting healthcare spending. Competition from hospital-based laboratories and new entrants using advanced AI-driven diagnostics may pressure margins over time. Supply chain disruptions for specialized reagents or equipment could temporarily halt testing capacity in specific geographic regions.
What is DGX's competitive advantage?
Quest Diagnostics benefits from a massive nationwide laboratory network that enables rapid sample collection and processing, creating a significant logistical moat against competitors. The company possesses deep expertise in high-volume molecular testing and rare disease diagnostics, allowing it to serve as a primary partner for major pharmaceutical companies in clinical trials. Its extensive automation infrastructure and proprietary test menus provide cost efficiencies and scalability that smaller regional labs cannot match.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.